Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study
Matteo Clavarezza(Ente Ospedaliero Ospedali Galliera), Marco Venturini(Ente Ospedaliero Ospedali Galliera), Giorgio Mustacchi(University of Trieste), Francesco Carrozza(Ospedale per gli Infermi), Paolo Marchetti(Istituto Dermopatico dell'Immacolata), Evaristo Maiello(Casa Sollievo della Sofferenza), Vincenzo Adamo(University of Messina), Davide Dondi(Sanofi (Italy)), Lucia Del Mastro(Ospedale Policlinico San Martino), Francesco Giotta(Istituto Tumori Bari), A. De Matteis(Università Cattolica del Sacro Cuore), Andrea Casadei‐Gardini(Vita-Salute San Raffaele University), D. Amoroso(Ospedale Versilia), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Enrico Aitini, Stefania Gori(Ospedale Sacro Cuore Don Calabria)
Cited by 8
Related Papers
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830